COVID-19 Test Detects, Identifies Specific Variants with 100% Accuracy

In a study, the RNA-encoded viral nucleic acid analytic reporter correctly determined the alpha, gamma, delta, epsilon and omicron genetic mutations in nasopharyngeal clinical samples. This ability could enable healthcare providers to make personalized treatment decisions for improved patient care.

A team of researchers at the University of California, Irvine (Irvine, CA, USA) a have published a paper on their research that describes the design and validation of the Revealr SARS-CoV-2 genotyping system. The team analyzed 34 clinical samples collected in early, mid- and late 2021 from patients experiencing COVID-19 symptoms. The RNA was isolated from the nasopharyngeal swabs, and the correct SARS-CoV-2 variant was identified in every case.

“The COVID-19 pandemic has created an urgent need for individualized diagnostic tools that can recognize the presence of the virus as well as the particular strain. Identifying and triaging patients infected with variants that increase viral transmissibility and reduce vaccine protection is critical to controlling spread of the disease,” said corresponding author John Chaput, UCI professor of pharmaceutical sciences. “Revealr goes beyond simple COVID detection methods, such as the commonly used antigen kit, to identify the precise SARS-CoV-2 strain infecting a patient.”

“Although Revealr was developed as a COVID detection assay, the next step is to expand to other respiratory tract infections that share symptoms with COVID-19, like influenza,” Chaput said. “The ability to distinguish single-point mutation in a DNA or RNA genetic sequence makes it ideally suited for any genotyping, including cancer. Beyond human health, Revealr could find use in forensic or agricultural applications that currently rely on DNA sequencing.”

Related Links:
University of California, Irvine